Evidence map›Paper›PMID 36225639›Full record

ArticleAmerican journal of cancer research2022

Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.

Wanying Liu, Qingqing Cai, Tiantian Yu, Paolo Strati, Frederick B Hagemeister, Qiongli Zhai, Mingzhi Zhang, Ling Li, Xiaosheng Fang, Jianyong Li and 11 more

Abstract read
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  6. Article
  7. Review
  8. Computed tomography findings of idiopathic multicentric Castleman disease subtypes.Journal of clinical and experimental hematopathology : JCEH · 2024
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Wanying LiuDepartment of Hematology and Oncology, The Second Affiliated Hospital of NanChang University NanChang, China.
Qingqing CaiState Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center Guangzhou, China.
Tiantian YuDepartment of Hematology and Oncology, The Second Affiliated Hospital of NanChang University NanChang, China.
Paolo StratiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Frederick B HagemeisterDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Qiongli ZhaiDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin, China.
Mingzhi ZhangDepartment of Medical Oncology, Zhengzhou University Cancer Center Zhengzhou, China.
Ling LiDepartment of Medical Oncology, Zhengzhou University Cancer Center Zhengzhou, China.
Xiaosheng FangDepartment of Hematology and Oncology, Shandong Cancer Hospital Shandong, China.
Jianyong LiDepartment of Hematology and Oncology, Jiangsu Province Hospital, Nanjing University Nanjing, China.
Ruifang SunDepartment of Pathology, Shanxi Cancer Hospital Shanxi, China.
Shanxiang ZhangDepartment of Pathology, Indiana University School of Medicine Indianapolis, IN, USA.
Hanjin YangDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, China.
Zhaoming WangDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, China.
Wenbian QianDepartment of Hematology and Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, China.
Noriko IwakiDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University Kanazawa, Japan.
Yasuharu SatoDivision of Pathophysiology, Okayama University Graduate School of Health Sciences Okayama, Japan.
Eric OksenhendlerDépartement d'Immunologie Clinique, Hôpital Saint-Louis Paris, France.
Zijun Y Xu-MonetteDivision of Hematopathology and Department of Pathology, Duke University Medical Center Durham, NC, USA.
Ken H YoungDivision of Hematopathology and Department of Pathology, Duke University Medical Center Durham, NC, USA.
Li YuDepartment of Hematology and Oncology, The Second Affiliated Hospital of NanChang University NanChang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Castleman disease (CD) has been reported as a group of poorly understood lymphoproliferative disorders, including unicentric CD (UCD) and idiopathic multicentric CD (iMCD) which are human immunodeficiency virus (HIV) negative and human herpes virus 8 (HHV-8) negative. The clinical and independent prognostic factors of CD remain poorly elucidated. We retrospectively collected the clinical information of 428 patients with HIV and HHV-8 negative CD from 12 large medical centers with 15-year follow-up. We analyzed the clinicopathologic features of 428 patients (248 with UCD and 180 with iMCD) with a median age of 41 years. The histology subtypes were hyaline-vascular (HV) histopathology for 215 patients (56.58%) and plasmacytic (PC) histopathology for 165 patients (43.42%). Most patients with UCD underwent surgical excision, whereas the treatment strategies of patients with iMCD were heterogeneous. The outcome for patients with UCD was better than that for patients with iMCD, 5-year overall survival (OS) rates were 95% and 74%, respectively. In further analysis, a multivariate analysis using a Cox regression model revealed that PC subtype, hepatomegaly and/or splenomegaly, hemoglobin ≤ 80 g/L, and albumin ≤ 30 g/L were independent prognostic factors of CD for OS. The model of iMCD revealed that age > 60 years, hepatomegaly and/or splenomegaly, and hemoglobin ≤ 80 g/L were independent risk factors. In UCD, single-factor analysis identified two significant risk factors: hemoglobin ≤ 100 g/L and albumin ≤ 30 g/L. Our study emphasizes the distinction of clinical characteristics between UCD and iMCD. The importance of poor risk factors of different clinical classifications may direct more precise and appropriate treatment strategies.

Indexed as

Castleman diseaseclinical characteristicsrisk prognostic factorstreatment

Identifiers

PMID36225639
PMCPMC9548017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.